Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
5-day change
1st Jan Change
1.05
USD
-6.25%
+6.06%
+42.86%
AcelRx Pharmaceuticals, Inc. announced that it has received $9.997996 million in funding
On July 202, 2023, AcelRx Pharmaceuticals, Inc. closed the transaction. The transaction included participation from 10 investors.
Talphera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 06
CI
Transcript : Talphera, Inc., Q4 2023 Earnings Call, Mar 06, 2024
Mar. 06
Talphera, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Mar. 06
CI
Talphera, Inc. Announces Management Changes
Mar. 01
CI
Talphera, Inc. Appoints Abhinav Jain to Serve as a Class II Director
Jan. 22
CI
XOMA Acquires Interest in Pain Management Medication Dsuvia for $8 Million
Jan. 18
MT
XOMA Corporation acquired DSUVIA® of Talphera, Inc. for $8 million.
Jan. 17
CI
Talphera, Inc. announced that it expects to receive $16 million in funding from Nantahala Capital Management, LLC, Rosalind Advisors, Inc.
Jan. 16
CI
AcelRx Pharmaceuticals, Inc. will Change its Ticker to TLPH from ACRX
Jan. 10
CI
Talphera Expects to Initiate the Registrational Study of Niyad
Jan. 09
CI
Talphera, Inc.(NasdaqGM:TLPH) dropped from NASDAQ Composite Index
Jan. 09
CI
AcelRx Pharmaceuticals, Inc. has Changed its Name to Talphera, Inc
Jan. 09
CI
Transcript : AcelRx Pharmaceuticals, Inc. - Special Call
Dec. 06
Transcript : AcelRx Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Nov. 08
AcelRx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023
Nov. 08
CI
AcelRx Pharmaceuticals, Inc. Receives IDE Approval for Niyad and Advances to A Single Registration Study
23-10-03
CI
Alliance Global Initiates AcelRx Pharmaceuticals at Buy With $4.25 Price Target
23-10-02
MT
HC Wainwright Adjusts AcelRx Pharmaceuticals Price Target to $5 From $8, Maintains Buy Rating
23-09-25
MT
North American Morning Briefing : Focus Shifts to -2-
23-08-21
DJ
HC Wainwright Upgrades AcelRx Pharmaceuticals to Buy From Neutral, Price Target is $8
23-08-18
MT
Transcript : AcelRx Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 10, 2023
23-08-10
AcelRx Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-10
CI
WPD Pharmaceuticals Sp zoo announced that it expects to receive PLN 10.2 million in funding from AcelRx Pharmaceuticals, Inc.
23-08-08
CI
AcelRx Pharmaceuticals, Inc. announced that it has received $9.997996 million in funding
23-07-19
CI
AcelRx Pharmaceuticals Enters Deal for $10 Million Private Placement of Common Shares, Warrants
23-07-18
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The Company is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.
More about the company
Last Close Price
1.05
USD
Average target price
5.125
USD
Spread / Average Target
+388.10%
Consensus
1st Jan change
Capi.
+42.86% 17.82M +5.31% 70.44B +10.97% 8.94B -16.83% 4.75B +43.48% 4.5B +3.20% 3.85B -21.36% 2.34B -29.67% 2.2B +8.38% 1.96B +3.90% 1.65B
Specialty & Advanced Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
TALPHERA, INC. 
